Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Up 5.3%

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) traded up 5.3% on Wednesday . The stock traded as high as $7.24 and last traded at $7.12. 1,385,716 shares traded hands during trading, a decline of 76% from the average session volume of 5,842,706 shares. The stock had previously closed at $6.76.

Analyst Ratings Changes

A number of brokerages have recently commented on RXRX. Jefferies Financial Group lowered their price objective on Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating for the company in a research report on Tuesday, September 3rd. Leerink Partners dropped their price objective on shares of Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating on the stock in a research report on Tuesday, September 3rd. KeyCorp reduced their price objective on shares of Recursion Pharmaceuticals from $16.00 to $12.00 and set an “overweight” rating on the stock in a report on Thursday, July 11th. Finally, Needham & Company LLC lowered their target price on shares of Recursion Pharmaceuticals from $16.00 to $11.00 and set a “buy” rating for the company in a research note on Wednesday, September 4th. Four equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $9.40.

Recursion Pharmaceuticals Stock Up 0.4 %

The firm’s 50-day moving average price is $7.20 and its two-hundred day moving average price is $8.42. The company has a debt-to-equity ratio of 0.04, a quick ratio of 6.07 and a current ratio of 6.07. The firm has a market cap of $1.95 billion, a PE ratio of -4.34 and a beta of 0.82.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.05). Recursion Pharmaceuticals had a negative net margin of 755.37% and a negative return on equity of 79.47%. The company had revenue of $14.42 million during the quarter, compared to analysts’ expectations of $11.96 million. During the same period last year, the firm earned ($0.38) earnings per share. Recursion Pharmaceuticals’s revenue was up 30.9% on a year-over-year basis. As a group, equities research analysts expect that Recursion Pharmaceuticals, Inc. will post -1.58 EPS for the current fiscal year.

Insider Activity at Recursion Pharmaceuticals

In other Recursion Pharmaceuticals news, Director Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock in a transaction that occurred on Tuesday, June 25th. The stock was sold at an average price of $9.51, for a total transaction of $108,860.97. Following the transaction, the director now owns 7,177,116 shares of the company’s stock, valued at $68,254,373.16. The transaction was disclosed in a filing with the SEC, which is available at this link. In other news, COO Tina Marriott sold 6,000 shares of the company’s stock in a transaction dated Thursday, June 27th. The shares were sold at an average price of $7.21, for a total value of $43,260.00. Following the completion of the sale, the chief operating officer now directly owns 535,457 shares of the company’s stock, valued at $3,860,644.97. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Blake Borgeson sold 11,447 shares of the firm’s stock in a transaction dated Tuesday, June 25th. The stock was sold at an average price of $9.51, for a total value of $108,860.97. Following the transaction, the director now directly owns 7,177,116 shares in the company, valued at approximately $68,254,373.16. The disclosure for this sale can be found here. Insiders sold a total of 243,129 shares of company stock valued at $1,742,165 in the last three months. 15.75% of the stock is currently owned by company insiders.

Institutional Trading of Recursion Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Mubadala Investment Co PJSC acquired a new position in shares of Recursion Pharmaceuticals in the fourth quarter valued at approximately $128,041,000. ARK Investment Management LLC increased its stake in Recursion Pharmaceuticals by 14.5% in the 2nd quarter. ARK Investment Management LLC now owns 28,142,918 shares of the company’s stock valued at $211,072,000 after buying an additional 3,555,357 shares during the period. Norges Bank purchased a new position in Recursion Pharmaceuticals during the 4th quarter worth $34,825,000. Baillie Gifford & Co. lifted its stake in shares of Recursion Pharmaceuticals by 10.5% in the 2nd quarter. Baillie Gifford & Co. now owns 26,589,936 shares of the company’s stock worth $199,425,000 after acquiring an additional 2,522,132 shares during the period. Finally, Kinnevik AB publ boosted its holdings in shares of Recursion Pharmaceuticals by 14.4% in the second quarter. Kinnevik AB publ now owns 11,905,668 shares of the company’s stock valued at $89,293,000 after acquiring an additional 1,500,000 shares in the last quarter. 89.06% of the stock is owned by hedge funds and other institutional investors.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.